14.18
+2.74(+23.95%)
Currency In USD
| Previous Close | 11.44 |
| Open | 11.85 |
| Day High | 14.26 |
| Day Low | 11.81 |
| 52-Week High | 19.93 |
| 52-Week Low | 7.75 |
| Volume | 83,205 |
| Average Volume | 28,288 |
| Market Cap | 106.4M |
| PE | -2.12 |
| EPS | -6.69 |
| Moving Average 50 Days | 10.79 |
| Moving Average 200 Days | 14.33 |
| Change | 2.74 |
If you invested $1000 in Assembly Biosciences, Inc. (ASMB) 10 years ago, it would be worth $88.58 as of May 04, 2025 at a share price of $14.18. Whereas If you bought $1000 worth of Assembly Biosciences, Inc. (ASMB) shares 5 years ago, it would be worth $66.54 as of May 04, 2025 at a share price of $14.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
GlobeNewswire Inc.
Apr 09, 2025 6:00 AM GMT
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation highlights new insights in geni
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokin
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
GlobeNewswire Inc.
Feb 20, 2025 1:00 PM GMT
– ABI-1179 was well-tolerated, with a half-life of approximately four days and high exposure across the dose range evaluated supporting the potential for once-weekly oral administration at a low dose – – Assembly Bio to move ABI-1179 directly into Ph